BioCardia vs Talphera
BCDA and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCDA and TLPH compare
Talphera is the larger company, worth 3.9 times as much as BioCardia ($54.5M against $14.0M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCDA | TLPH |
|---|---|---|
| Size and price | ||
| Market cap | $14.0M | $54.5M |
| Share price | $0.922 | $1.05 |
| Change, 1 year | −28.6% | −17.3% |
| Change, 5 years | −97.2% | −92.7% |
| Beta (5Y) | 1.02 | 0.64 |
| Employees | 21 | 12 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 54501× |
| P/B | 5.2× | 3.8× (better) |
| FCF yield | −54.3% | – |
| Growth | ||
| Revenue growth (TTM) | – | −96.3% |
| Revenue growth, 5Y average | – | −65.1% |
| Profitability | ||
| Operating margin | – | −1474700% |
| Net margin | – | −1507600% |
| Return on equity | −1803% | −143% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.09 | 4.29 (better) |
| Altman Z-score | −51.20 | −23.55 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −86.7% | – |
| Shareholder yield | −86.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 8.8% | 54.4% |
| Held by insiders | 11.7% | 46.8% |
| Insider net buying, 12 months | $170K | $304K (better) |
| Short interest, % of float | 5.5% | 4.4% |
Go deeper
- BCDA stock overview
- BCDA income statement
- BCDA valuation and score
- TLPH stock overview
- TLPH income statement
- TLPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.